Browsing by Author Abdi, Ehtesham A

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 7 of 7
Issue DateTitleAuthor(s)Citation
2007Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial.Beale, Philip; Carter, Candace; Dhillon, Haryana; Heritier, Stephane; Hickie, Ian; O'Connell, Rachel; Simes, Robert John; Stockler, Martin; Wilcken, Nicholas; Abdi, Ehtesham A; Glasgow, Amanda; Goldstein, David; Jefford, Michael; Nowak, Anna K.; Turner, Jane; Wyld, David; Central Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Central Clinical School: Brain & Mind Research Institute; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Western Clinical School: Medicine (Westmead)Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial., Lancet Oncology, vol.8,(7),2007,pp 603-612
2010Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomasBrown, Christopher; Gainford, Mary; Gebski, Val; Miller, Danielle; Abdi, Ehtesham A; Ackland, Stephen P.; Goldstein, D; Jefford, Michael; Selva-Nayagam, Sid; Shannon, Jenny; Tebbutt, Niall C; van Hazel, Guy; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreFixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas, Cancer Chemotherapy and Pharmacology, vol.0, 0,pp 1-7
2016Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group Trial 22-00Coates, Alan; Abdi, Ehtesham A; Colleoni, Marco; et al, Various; Gelber, S.; Gianni, Lorenzo; Gomez, Henry; Gray, Katherine P; Lang, Istvan; Linderholm, Barbro K; Thurlimann, Beat; School of Public Health: Public HealthLow-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group Trial 22-00, Journal of Clinical Oncology, vol.34, 28, 2016,pp 3400-3408
2016Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group Trial 22-00Coates, Alan; Abdi, Ehtesham A; Colleoni, Marco; et al, Various; Gelber, S.; Gianni, Lorenzo; Gomez, Henry; Gray, Katherine P; Lang, Istvan; Linderholm, Barbro K; Thurlimann, Beat; School of Public Health: Public HealthLow-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group Trial 22-00, Journal of Clinical Oncology, vol.34, 28, 2016,pp 3400-3408
2013The Median Informs the Message: Accuracy of Individualized Scenarios for Survival Time Based on Oncologists' EstimatesBeale, Philip; Kiely, Belinda Emma; Martin, Andrew; Stockler, Martin; Tattersall, Martin; Wilcken, Nicholas; Abdi, Ehtesham A; Glare, Paul A.; Glasgow, Amanda; Goldstein, David; Jefford, Michael; Nowak, Anna K.; Wyld, David; Central Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Central Clinical School: Medicine; Western Clinical School: Medicine (Westmead)The Median Informs the Message: Accuracy of Individualized Scenarios for Survival Time Based on Oncologists' Estimates, Journal of Clinical Oncology, vol.31, 28, 2013,pp 3565-3571
2009A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma.Kefford, Richard (Rick); Abdi, Ehtesham A; Beith, Jane M.; Corrie, P; Kotasek, Dusan; Margison, G. P.; Middleton, M. R.; Mortimer, P.; Palmer, C; Ranson, M.; Thomas, N; Watson, A. J.; Western Clinical School: Westmead Millennium InstituteA phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma., British Journal of Cancer, vol.100,(8),2009,pp 1245-1249
2011Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumabCummins, Michelle; Marx, Gavin; Shannon, Jenny; Simes, Robert John; Wilson, Kate; Zannino, Diana; Abdi, Ehtesham A; Blum, R; Chantrill, L; Goldstein, D; Karapetis, Christos; Lowenthal, Raymond M.; Murphy, F; Nayagam, S; Price, Timothy; Strickland, A. H.; Tebbutt, Niall C; School of Public Health: NH&MRC Clinical Trials Centre; Medicine; Nepean Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreRisk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab, Annals of Oncology, vol.22, 8, 2011,pp 1834-1838